Natalia Rodriguez-Spiteri

Natalia Rodriguez-Spiteri

Auto-generated profile, based on publicly available information

Natalia Rodriguez-Spiteri

Breast Surgical Oncology Unit, Clinica Universidad de Navarra, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2009 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
AGA. Gil‐Rendo
A. Gil‐Rendo
FMF. Martínez‐Regueira
F. Martínez‐Regueira
GZG. Zornoza
G. Zornoza
MGMaria Garcia-Velloso
Maria Garcia-Velloso
CBC. Beorlegui
C. Beorlegui
NRN. Rodriguez‐Spiteri
N. Rodriguez‐Spiteri
Background: This study analysed the correlation between [18F]fluorodeoxyglucose (FDG) uptake assessed by positron emission tomography (PET) in breast tumours, and histopathological and inmunohistochemical prognostic factors. Methods: FDG–PET was performed before surgery in 275 women with primary breast cancer. The standarized uptake value (SUV) was compared with histopathological findings after surgery. Results: A positive relationship was found between the SUV and tumour size (r = 0·46, P < 0·001), axillary lymph node status (P < 0·001), histological type (P < 0·001), histological grade (P < 0·001), oestrogen receptor status (P < 0·001), p53 (P < 0·001) and Ki‐67 (P < 0·001) expression. Multivariable linear regression showed that tumour size, histological grade, Ki‐67 expression, oestrogen receptor status and histological type were significantly related to the SUV. Conclusion: The SUV is a preoperative and non‐invasive metabolic factor that relates to some prognostic factors in breast cancer. Copyright © 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

15 June 2005 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GBGorka Bastarrika
Gorka Bastarrika
MGMaría José García-Velloso
María José García-Velloso
MLMaria Dolores Lozano
Maria Dolores Lozano
UMUsua Montes
Usua Montes
WTWenceslao Torre
Wenceslao Torre
JZJavier J. Zulueta
Javier J. Zulueta
Rationale: Lung cancer screening using computed tomography (CT) is effective in detecting lung cancer in early stages. Concerns regarding false-positive rates and unnecessary invasive procedures have been raised. Objective: To study the efficiency of a lung cancer protocol using spiral CT and F-18-fluorodeoxyglucose positron emission tomography (FDG-PET). Methods: High-risk individuals underwent screening with annual spiral CTs. Follow-up CTs were done for noncalcified nodules of 5 mm or greater, and FDG-PET was done for nodules 10 mm or larger or smaller (> 7 mm), growing nodules. Results: A total of 911 individuals completed a baseline CT study and 424 had at least one annual follow-up study. Of the former, 14% had noncalcified nodules of 5 mm or larger, and 3.6% had nodules of 10 mm or larger. Eleven non–small cell lung cancers (NSCLC) and one small cell lung cancer (SCLC) were diagnosed in the baseline study (prevalence rate, 1.32%), and two NSCLCs in the annual study (incidence rate, 0.47%). All NSCLCs (92% of prevalence cancers) were diagnosed in stage I (12 stage IA, 1 stage IB). FDG-PET was helpful for the correct diagnosis in 19 of 25 indeterminate nodules. The sensitivity, specificity, positive predictive value, and negative predictive value of FDG-PET for the diagnosis of malignancy were 69, 91, 90, and 71%, respectively. However, the sensitivity and negative predictive value of the screening algorithm, which included a 3-month follow-up CT for nodules with a negative FDG-PET, was 100%. Conclusion: A protocol for early lung cancer detection using spiral CT and FDG-PET is useful and may minimize unnecessary invasive procedures for benign lesions.

1 July 2016 in Brachytherapy
Verified
Journal Article
Closed access
MCMauricio Cambeiro
Mauricio Cambeiro
FMFernando Martinez-Regueira
Fernando Martinez-Regueira
NRNatalia Rodriguez-Spiteri
Natalia Rodriguez-Spiteri
BOBegoña Olartecoechea
Begoña Olartecoechea
LILuis Pina Insausti
Luis Pina Insausti
RMRafael Martínez-Monge
Rafael Martínez-Monge

1 September 2008 in Diagnostic Molecular Pathology
Verified
Journal Article
Closed access
JPJavier Pardo
Javier Pardo
GAGregorio Aisa
Gregorio Aisa
ENRIQUE DE ALAVAENRIQUE DE ALAVA
ENRIQUE DE ALAVA
JSJesús J. Sola
Jesús J. Sola
APAngel Panizo
Angel Panizo
WTWenceslao Torre
Wenceslao Torre
Carcinosarcomas are malignant tumors with a mixture of carcinomatous and differentiated sarcomatous elements. We investigate the morphology, immunohistochemistry, and comparative genomic hybridization analysis of 3 mixed squamous carcinoma and osteosarcoma of the lung. All patients were male and their ages were 72, 43, and 58 years. The sizes of the neoplasms were 7, 5, and 5 cm in maximum diameter, respectively. Two patients died of the disease 9 and 14 months after surgery; and one is alive 6 months later. By light microscopy, all cases had both squamous and osteosarcomatous structures. Immunohistochemistry was positive for AE3AE1, p63, 34 E12, CAM 5.2 (2/3 cases), CK-7 (2/3 cases), epithelial membrane antigen, E-cadherin, p53, and carcinogenic embryonic antigen in carcinomatous areas, and for vimentin and CD-68 in sarcomatous component. Areas of transition positive for both cytokeratins and vimentin were seen in all cases. A total of 55 copy number changes were detected with a median of 18 abnormalities per case: 48 gains, 6 losses, and 1 high-level amplification. Chromosome alterations in osteosarcomatous areas were similar to those found in lung metastatic osteosarcoma, comparable to those found in carcinomatous areas and to lung squamous carcinomas. Coincidences between carcinomatous areas and osteosarcomatous zones were found as gains in chromosomes 1q, 3q, 5p, 8q, and 12p. These findings provide arguments that favor a common origin for both types of cells, supported by the mixture of cells, the existence of undifferentiated cells positive to both cytokeratin and vimentin markers, and the CGH overlaps of chromosomal gains between carcinomatous and sarcomatous areas.

1 January 2006 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
MVMarta Valero
Marta Valero
JBJosé F Boán
José F Boán
NRNatalia Rodriguez-Spiteri
Natalia Rodriguez-Spiteri
WTWenceslao Torre
Wenceslao Torre
JRJosé A Richter
José A Richter

5 April 2022 in Brachytherapy
Verified
Journal Article
Closed access
MMMarta Gimeno Morales
Marta Gimeno Morales
RMRafael Martínez-Monge
Rafael Martínez-Monge
FMFernando Martínez-Regueira
Fernando Martínez-Regueira
NRNatalia Rodriguez-Spiteri
Natalia Rodriguez-Spiteri
BOBegoña Olartecoechea
Begoña Olartecoechea
MCMauricio Cambeiro
Mauricio Cambeiro